FDA approves Trulign toric accommodating IOL
The Trulign toric accommodating posterior chamber IOL has been approved by the U.S. Food and Drug Administration, according to a news release from Bausch + Lomb.
The lens, which corrects for astigmatism and can improve vision across a natural range of focus, is meant for primary implantation in the capsular bag for visual correction of aphakia, as well as postoperative refractive astigmatism secondary to the removal of a cataractous lens, the release said.
It is intended for use in adult patients with or without presbyopia who seek reduction of residual refractive cylinder and increased spectacle independence.
The Trulign, a toric model of Bausch + Lomb’s Crystalens models AT-50SE and AT-52SE, demonstrated improved uncorrected near, intermediate and distance vision in an FDA clinical trial. Its haptic design resulted in 96.1% of lenses rotating fewer than 5° between surgery and at 4- to 6-months post-op, the release said.